ERFE and thalassemia: The therapeutic potential of targeting ERFE has been demonstrated through the development of anti-ERFE antibodies that prevent hepcidin suppression and ameliorate murine thalassemia by specifically targeting the N-terminal domain of erythroferrone (ERFE) (16).